Cyclin-Dependent Kinase Inhibitor Pipeline Review | Latest Drug Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Syros Pharmaceuticals, Exelixis, Prelude Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cyclin-Dependent Kinase Inhibitor pipeline constitutes 40+ key companies continuously working towards developing 40+ Cyclin-Dependent Kinase Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Cyclin-Dependent Kinase Inhibitor Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cyclin-Dependent Kinase Inhibitor Market.

The Cyclin-Dependent Kinase Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cyclin-Dependent Kinase Inhibitor Pipeline Report: https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Cyclin-Dependent Kinase Inhibitor treatment therapies with a considerable amount of success over the years.
• Cyclin-Dependent Kinase Inhibitor companies working in the treatment market are Syros Pharmaceuticals, Exelixis, Prelude Therapeutics, Blueprint Medicines, Vincerx Pharma, Jiangsu Hengrui Medicine Co., Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Genor Pharma, Jiangsu Hengrui Medicine Co., Vincerx Pharma, Aucentra Therapeutics, and others, are developing therapies for the Cyclin-Dependent Kinase Inhibitor treatment
• Emerging Cyclin-Dependent Kinase Inhibitor therapies in the different phases of clinical trials are- SY-5609, XL 102, PRT3645, BLU 222, Enitociclib, SHR-6390, Milciclib, XZP 3287, Abemaciclib, GB491 (lerociclib), SHR6390, Enitociclib, Auceliciclib, AU2-94, and others are expected to have a significant impact on the Cyclin-Dependent Kinase Inhibitor market in the coming years.
• In April 2023, Insilico Medicine reported that it had used a structure-based generative chemistry method made possible by the Chemistry42 multi-modal generative reinforcement learning platform to successfully discover a potent, selective, and orally bioavailable small molecule inhibitor of CDK8 for the treatment of cancer. A major journal in medical chemistry, the Journal of medical Chemistry of the American Chemical Society, published the research
• In April 2023, According to Sumitomo Pharma Oncology, Inc., TP-1287, an experimental oral CDK9 inhibitor, has been given Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Ewing sarcoma. The CDK9 inhibitor alvocidib has an experimental oral phosphate prodrug called TP-1287
• In March 2023, In order to evaluate its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene's BTK inhibitor, zanubrutinib, in hematologic malignancies, Prelude Therapeutics Incorporated (Prelude) announced a clinical trial collaboration with BeiGene. According to the terms of the clinical trial partnership agreement, Prelude will be given all global operational, development, and commercialization rights and obligations for PRT2527 while BeiGene will give zanubrutinib to BeiGene
• In September 2022, The U.S. Food and medication Administration (FDA) has designated SY-5609 as an orphan medication for the treatment of pancreatic cancer, according to a statement from Syros Pharmaceuticals, Inc. Patients with recurrent metastatic pancreatic cancer are currently being treated with chemotherapy plus SY-5609, a very powerful and selective oral cyclin-dependent kinase 7 (CDK7) inhibitor.
• In November 2021, Abemaciclib versus placebo in a Phase III, randomised, double-blind research was started by Eli Lilly and Company for patients with advanced, dedifferentiated liposarcoma. Patients with advanced, recurring, and/or metastatic DDLS are participating in this multicenter, placebo-controlled trial.

Cyclin-Dependent Kinase Inhibitor Overview
Cyclin-dependent kinase inhibitor protein, sometimes referred to as CKIs, CDIs, or CDKIs, is a protein that blocks the action of the enzymes cyclingdependent kinase (CDK) and Cyclin by halting the cell cycle in the presence of unfavourable circumstances. As a result, it acts as a tumour suppressor.

Get a Free Sample PDF Report to know more about Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Cyclin-Dependent Kinase Inhibitor Drugs Under Different Phases of Clinical Development Include:
• SY-5609: Syros Pharmaceuticals
• XL 102: Exelixis
• PRT3645: Prelude Therapeutics
• BLU 222: Blueprint Medicines
• Enitociclib: Vincerx Pharma
• SHR-6390: Jiangsu Hengrui Medicine Co.
• Milciclib: Tiziana Life Sciences
• XZP 3287: Xuanzhu Biopharmaceutical
• Abemaciclib: Eli Lilly and Company
• GB491 (lerociclib): Genor Pharma
• SHR6390: Jiangsu Hengrui Medicine Co.
• Enitociclib: Vincerx Pharma
• Auceliciclib: Aucentra Therapeutics
• AU2-94: Aucentra Therapeutics

Cyclin-Dependent Kinase Inhibitor Route of Administration
Cyclin-Dependent Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule

Cyclin-Dependent Kinase Inhibitor Molecule Type
Cyclin-Dependent Kinase Inhibitor Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutics Assessment
• Cyclin-Dependent Kinase Inhibitor Assessment by Product Type
• Cyclin-Dependent Kinase Inhibitor By Stage and Product Type
• Cyclin-Dependent Kinase Inhibitor Assessment by Route of Administration
• Cyclin-Dependent Kinase Inhibitor By Stage and Route of Administration
• Cyclin-Dependent Kinase Inhibitor Assessment by Molecule Type
• Cyclin-Dependent Kinase Inhibitor by Stage and Molecule Type

DelveInsight's Cyclin-Dependent Kinase Inhibitor Report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Cyclin-Dependent Kinase Inhibitor product details are provided in the report. Download the Cyclin-Dependent Kinase Inhibitor pipeline report to learn more about the emerging Cyclin-Dependent Kinase Inhibitor therapies at:
https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Cyclin-Dependent Kinase Inhibitor Therapeutics Market include:
Key companies developing therapies for Cyclin-Dependent Kinase Inhibitor are - Syros Pharmaceuticals, Jiangsu Hengrui Medicine, Aucentra Therapeutics, MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer, Novartis Pharmaceuticals, TYK Medicine, BioTheryX, Concarlo Therapeutics, Eli Lilly and Company, Kronos Bio, OnQuality Pharmaceuticals, Incyte Corporation, G1 Therapeutics, Blueprint Medicines, Cyclacel Pharmaceuticals, Nerviano Medical Sciences, Vichem Chemie, Prelude Therapeutics, Exelixis, -Qurient Co. Ltd., Kirilys Therapeutics, Sumitomo Pharma Oncology, Insilico Medicine, Cedilla Therapeutics, Relay Therapeutics, and others.

Cyclin-Dependent Kinase Inhibitor Pipeline Analysis:
The Cyclin-Dependent Kinase Inhibitor pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cyclin-Dependent Kinase Inhibitor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cyclin-Dependent Kinase Inhibitor Treatment.
• Cyclin-Dependent Kinase Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cyclin-Dependent Kinase Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cyclin-Dependent Kinase Inhibitor market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cyclin-Dependent Kinase Inhibitor drugs and therapies-
https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cyclin-Dependent Kinase Inhibitor Pipeline Market Drivers
• Rising prevalence of Cancer, increasing research and development projects for thelaunch of new drugs are some of the important factors that are fueling the Cyclin-Dependent Kinase Inhibitor Market.

Cyclin-Dependent Kinase Inhibitor Pipeline Market Barriers
• However, high cost associated with the treatment, side-effects associated with the Cyclin-Dependent Kinase Inhibitor immunotherapy and other factors are creating obstacles in the Cyclin-Dependent Kinase Inhibitor Market growth.

Scope of Cyclin-Dependent Kinase Inhibitor Pipeline Drug Insight
• Coverage: Global
• Key Cyclin-Dependent Kinase Inhibitor Companies: Syros Pharmaceuticals, Exelixis, Prelude Therapeutics, Blueprint Medicines, Vincerx Pharma, Jiangsu Hengrui Medicine Co., Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Genor Pharma, Jiangsu Hengrui Medicine Co., Vincerx Pharma, Aucentra Therapeutics, and others
• Key Cyclin-Dependent Kinase Inhibitor Therapies: SY-5609, XL 102, PRT3645, BLU 222, Enitociclib, SHR-6390, Milciclib, XZP 3287, Abemaciclib, GB491 (lerociclib), SHR6390, Enitociclib, Auceliciclib, AU2-94, and others
• Cyclin-Dependent Kinase Inhibitor Therapeutic Assessment: Cyclin-Dependent Kinase Inhibitor current marketed and Cyclin-Dependent Kinase Inhibitor emerging therapies
• Cyclin-Dependent Kinase Inhibitor Market Dynamics: Cyclin-Dependent Kinase Inhibitor market drivers and Cyclin-Dependent Kinase Inhibitor market barriers

Request for Sample PDF Report for Cyclin-Dependent Kinase Inhibitor Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Cyclin-Dependent Kinase Inhibitor Report Introduction
2. Cyclin-Dependent Kinase Inhibitor Executive Summary
3. Cyclin-Dependent Kinase Inhibitor Overview
4. Cyclin-Dependent Kinase Inhibitor- Analytical Perspective In-depth Commercial Assessment
5. Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutics
6. Cyclin-Dependent Kinase Inhibitor Late Stage Products (Phase II/III)
7. Cyclin-Dependent Kinase Inhibitor Mid Stage Products (Phase II)
8. Cyclin-Dependent Kinase Inhibitor Early Stage Products (Phase I)
9. Cyclin-Dependent Kinase Inhibitor Preclinical Stage Products
10. Cyclin-Dependent Kinase Inhibitor Therapeutics Assessment
11. Cyclin-Dependent Kinase Inhibitor Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cyclin-Dependent Kinase Inhibitor Key Companies
14. Cyclin-Dependent Kinase Inhibitor Key Products
15. Cyclin-Dependent Kinase Inhibitor Unmet Needs
16 . Cyclin-Dependent Kinase Inhibitor Market Drivers and Barriers
17. Cyclin-Dependent Kinase Inhibitor Future Perspectives and Conclusion
18. Cyclin-Dependent Kinase Inhibitor Analyst Views
19. Appendix
20. About DelveInsight

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.